Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Core Insights - Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases [1] Company Announcement - The company will hold a conference call and webcast on September 29 at 8:30 a.m. ET to share topline results from the Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults [1]